Royalty Report: Diagnostic, Medical, Disease – Collection: 28793

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Diagnostic
  • Medical
  • Disease
  • HIV / AIDs
  • Drugs
  • Pharmaceuticals
  • Diagnostic Substances
  • Biotechnology
  • Genome
  • Device
  • Test/Monitoring
  • Surgical
  • Molecular
  • Therapeutic
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28793

License Grant
The present Contract for the Transfer of Technology and Material calls for the scientific and technological co-operation between the Brazilian Licensee and the Licensor, for the production of the HIV ½ Stat-Pak.
License Property
The Licensor is a company having as its main purpose the production of lateral flow rapid diagnostic test kits including but not limited to Rapid test kit for HIV – HIV ½ Stat-Pak.

HIV 1/2 STAT-PAK® assay is a single use, immunochromatographic test used to detect antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in fingerstick whole blood, venous whole blood, serum and plasma specimens.

Field of Use
Rapid test kit for HIV ½ produced by the Licensee termed HIV ½Stat – Pak composed of tests based on immunochromatography and lateral low, adapted to rapid supports for use with serum, plasma or whole blood, sealed in individual laminated foil pouches containing also, lancets, transfer loops, band-aids and dessicants.

IPSCIO Record ID: 27549

License Grant
Pursuant to the Omnibus Agreement, beginning June 1, 2016, the Licensee will own full rights to the SURE CHECK® HIV 1/2 Assay, including a perpetual, non-exclusive, transferable, sub-assignable license, and  including sales, marketing, distribution and trademark rights. The agreement subject to the terms of an existing marketing and distribution agreement with a third party, granting it the U.S. marketing and distribution rights through May 31, 2016.
License Property
The SURE CHECK® HIV 1/2 Assay is a easy-to-use, self-contained, single-use collection and testing device for the rapid, visual detection of antibodies to HIV 1 and HIV 2.
Field of Use
The SURE CHECK® HIV 1/2 Assay is marketed exclusively in the U.S. as Clearview® Complete. Outside the U.S. The SURE CHECK® HIV 1/2 Assay is Food & Drug Administration (FDA) approved, CLIA-waived, European CE-marked, and has been pre-qualified by the World Health Organization (WHO). Results are obtained in 15 minutes via a 2.5uL blood sample (i.e., fingerstick, serum, plasma, or venipuncture whole blood). The assay is stable at room temperature and provides 99.7% sensitivity and 99.9% specificity.

IPSCIO Record ID: 7270

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor an exclusive worldwide license during the Term under the Licensor's Lateral Flow Patents to manufacture the HIV Barrel Product solely for sale to Inverness.
License Property
Licensor, among other activities, is in the business of developing, marketing and selling products used to diagnose various diseases, including HIV, and owns or has the right to grant licenses to a number of patents pertaining to HIV diagnosis, including the Inverness Lateral Flow Patents. Licensor asserts that the HIV Barrel Product is within the scope of the claims of the Licensor's Lateral Flow Patents.

HIV Barrel Product means the product for HIV testing known as SURE CHECK(R) HIV 1/2 as described in Licensee's PMA on file with the FDA and further described in the SURE CHECK(R) HIV 1/2 package insert, Catalog #HIV202, together with any improvements thereto.

HIV Cassette Product means the Licensee's product currently known as HIV 1/2 STAT PAK(TM) as described in Licensee's PMA on file with the FDA and further described in the HIV 1/2 STAT PAK(TM) package insert, Catalog #HIV 102, which is the subject of a Related Document.

Our main products presently commercially available are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA last year. These products employ single path lateral flow technology.  Lateral flow, whether single or dual path, generally refers to the process of a sample flowing from the point of application on a test strip to provide a test result on a portion of a strip downstream from either the point of application of the sample or of another reagent.

Field of Use
Barrel Field means diagnostic testing for the presence of HIV antibodies utilizing an integrated in-vitro diagnostic testing device that (i) is a single use disposable device (ii) collects a physiologic sample from a patient directly into the device and delivers that sample into a system contained in the device  where the reaction reagent medium (for example, a reagent strip) is enclosed in a barrel or other container with a transparent portion which allows the results of the reaction to be visible, designed to protect the user from contact with its contents, (iii) produces a visually readable result in less than 20 minutes, and (iv) is primarily designed to be used in a Point of Care environment or for self-testing by consumers.

IPSCIO Record ID: 26919

License Grant
The Company has taken a license to two U.S. patents, which expire in the financial years 2004 and 2014 respectively, covering the format of Uni-Gold(TM) rapid test device i.e. the visual result given by its one step strip test.
License Property
The Company 's Uni-Gold one step assays detect antibodies to various infectious diseases and conditions in serum and plasma or whole blood based on the principle of an immuno-chromatographic assay.  The Company currently markets four products based on this technology, Uni-Gold HIV, Uni-Gold Hepatitis B, Uni-Gold hCG (pregnancy) and Uni-Gold H. pylori.

IPSCIO Record ID: 29888

License Grant
The Parties entered into a manufacturing agreement. Licensee has exclusive rights to manufacture Hema-Strip and Sera-Strip on behalf of and under the label of the Company. The agreement also allows Licensee exclusive license to certain technology and production assets of the Licensor to be used in the manufacture of Licensee products.
License Property
Hema-Strip HIV ('Hema-Strip') is a single use test kit that collects, processes and analyzes a minute amount of whole blood to detect HIV antibodies.

IPSCIO Record ID: 159433

License Grant
Licensor of Singapore grants to Licensee a complete assignment and transfer (hereinafter referred to the Sub-License) of all of its rights under the License Agreement for the marketing, sale and distribution of the Products within India, for the term of this Sub-License Agreement and any extensions hereof.

In the event that Licensee demonstrates that Licensee can manufacture Licensor. Products of equal quality as those of Licensor of Singapore as determined by Licensor shall grant to Licensee a complete assignment and transfer of its rights to manufacture in India under the License Agreement (hereinafter referred to as the Manufacturing Rights) the Products for distribution and sale within India for the term of this Agreement and any extensions hereof, Licensor, recognizing that a grant hereunder of Manufacturing Rights will further the purposes of Licensor under the License Agreement, hereby consents to such grant of the Manufacturing Rights, Licensor shall have the right to establish, maintain and monitor quality control manufacturing standards (equal to those applicable to Licensor) which Licensee shall adhere to in its manufacturing operations.

License Property
Licensor has developed and is continuing to develop certain diagnostic products and procedures for the non-invasive or minimally-invasive collection and testing of saliva and blood to detect the presence of contagious diseases, including but not limited to HIV 1 & 2, Hepatitis B & C and TB (hereinafter included in the term 'Products').

Products shall include diagnostic products and procedures for the non-invasive or minimally-invasive collection and testing of saliva and blood to detect the presence of contagious diseases, including but not limited to, HIV 1 & 2, Hepatitis B & C, and TB; 'Omni-SAL'; 'SDS Sero-Strip'; and 'SDS Hema-Strip'; as well as all products and/or procedures which fall within the meaning of the following terms as those terms are defined in the License Agreement 'Invention', 'Improvements', 'Know-How', 'Licensed Marks', 'Licensed Products', and 'Other Licensed Products'.

Omni-SAL' shall mean that certain saliva collection device which is the subject matter of United States Patent Number 5,260,031, dated November 9, 1993, and any enhancements or improvements to the same, whether such enhancements or improvements are or are not covered by other patents.

SDS Sero-Strip' shall mean a dry rapid assay strip for HIV 1 & 2 which uses serum or plasma separated by centrifugation of whole blood obtained by phlebotomy, The actual test is accomplished by a proprietary method developed and owned by SDS Inc. that permits visual confirmation of the results.

SDS Hema-Strip' shall mean a dry rapid assay strip for HIV I & 2 to which whole blood obtained via finger prick is used; the separation of the serum occurs on the strip itself. The actual test is accomplished by a proprietary method developed and owned by SDS Inc. that permits visual confirmation of the results.

Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 289170

License Grant
Licensor grants to the Swiss Licensee a worldwide, semi-exclusive license, without the right to sublicense, under the Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Field.

For the Licensor Transplantation Field License, Licensor grants a worldwide, non-exclusive license, without the right to sublicense, under  Licensoe Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Transplantation Field.

License Property
The patent rights relate to the human immunodeficiency virus (HIV).

Products means reagents, compositions or kits suitable for use in the Field or the Transplantation Field.

Field of Use
The Licensee intended application is for use in assays for the detection of nucleic acid sequences for use in in vitro diagnostics (excusing use in Blood Screening, but without limiting the effect of the Blood Screening Agreement.

Field means the commercial use of human in vitro diagnostic products that detect nucleic acid sequences of HIV. Expressly excluded from the Field are products in Blood Screening; and products specifically labeled or promoted for use in the Transplantation Field.

Transplantation Field means the commercial use of products that detect nucleic acid sequences for the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors, other than the transfusion or transplantation of blood or its derivatives, components or replacements.

IPSCIO Record ID: 203343

License Grant
The parties previously entered a Clinical Diagnostics Agreement and Blood Screening Agreement.

Pursuant to the settlement, the parties hereby irrevocably stipulate the Licensor Licensed Patents in the Territory are valid and enforceable; and, the making, use, offer for sale, sale, or importation of any Licensee Product in the Territory, where a Licensor Licensed Patent has issued and prior to the expiration of such Licensor Licensed Patent, would, in the absence of the licenses granted in the Agreements, as applicable, constitute infringement of one or more claims of such Licensor Licensed Patent.

Per the original agreement, the Parties entered a nonexclusive license in the Territory, without the right to sublicense, under the Licensor Licensed Patents to make, import, use, offer for sale and sell Licensor Licensed Products for use in Blood Screening solely for sale to or use by or on behalf of Existing Customers under the Existing Agreements and Existing Offers.

License Property
The Licensee Products means all assays sold by Licensee for the detection, quantitation, genotyping or other analyses of nucleic acid sequences Directed to HIV for use in in vitro diagnostics and/or Blood Screening, including without limitation the following products of Licensee Amplicor HIV-1 test, v. 1.0; Amplicor HIV-1 Monitor test, v. 1.0; Amplicor HIV-1 Monitor test, v. 1.5; COBAS Amplicor HIV-1 Monitor test, v. 1.5; Ampliscreen HIV-1 test, v. 1.5; and COBAS Ampliscreen HIV-1 test, v. 1.5; and all versions and successors and substitutes therefor.

Blood Screening means the commercial use of products that detect nucleic acid sequence(s) for the screening of blood, plasma or blood components intended for transfusion or for use in blood products (e.g., without limitation, immunoglobulins); or confirmatory or supplemental testing of the same samples otherwise screened for purposes described.

Directed to HIV means that the claim or technology in question is directed to methods, compositions, reagents or kits specifically for use in nucleic acid-based diagnostic assays for the detection of HIV nucleic acid sequence(s), or specifically for use in the manufacture of any compositions or reagents for use in, or manufacture of nucleic acid-based diagnostic assays for detection of HIV nucleic acid sequence(s) (excluding, for example, polymerase chain reaction claims and technology and other methods for detection of nucleic acid sequence(s) generally which involve nucleic acid amplification).

HIV means any viral isolate of the human immunodeficiency virus classified as HIV by the International Committee on the Taxonomy of Viruses (or any body that replaces such Committee) or any subtype of such isolate and further includes any isolate that is at least forty percent (40%) homologous to any such isolate and of the same genomic type and substantially the same genomic organization, any isolate that has a genome that either hybridizes to or is substantially identical to any such isolate or its compliment, and any defective or modified form of any of the above isolates.

''Patent' means U.S. Patent No. 6,531,276 Bl

Field of Use
This agreement is for the HIV Qualitative Assay field.

IPSCIO Record ID: 4046

License Grant
The Company signed an Agreement with the Brazilian Licensee for the transfer of technology for patents applied in Brazil or other Mercosur countries for the term of the patents and the transfer of all technical information related to DPP® HIV 1/2 rapid test and the process to obtain rapid test for the detection of HIV1/2 by the DPP® technology.
License Property
This Agreement contemplates the scientific and technological co-operation between the Company and the Licensee for such activities so that the Licensee will be able to manufacture the DPP® technology in Brazil.  Under the Agreement, after the Product registration by Brazil’s National Health Surveillance Agency, the Company will supply product and the Licensee will do their best efforts to purchase each year for a period of three years from the Company the amount of 833,333 units of product at a product transfer price of $3.00 per unit for a minimum aggregate purchase obligation equal to $7.5M.  Following the purchase of $7.5 million, during each of the succeeding two years, Licensee will purchase test components as specified by Licensee at an aggregate purchase price of $1.25 million in each of the fourth and fifth year.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4321

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts a non-exclusive, royalty-bearing license during the Term, under the Inverness Lateral Flow Patents, to manufacture and to Exploit the HIV Cassette Products in the Rest of the World.
License Property
Licensor, among other activities, is in the business of developing, marketing and selling products used to diagnose various diseases, including HIV, and owns or has rights to grant licenses to a number of patents pertaining to HIV diagnosis, including the Licensor's Lateral Flow Patents. Licensor asserts that the HIV Cassette Product is within the scope of the claims of the Licensor's Lateral Flow Patents.

HIV Cassette Product means the Licensee product currently known as HIV 1/2 STAT PAK(TM) as described in Licensee's PMA on file with the FDA and further described in the HIV 1/2 STAT PAK(TM) package insert, Catalog #HIV 102, together with any improvements thereto.

Field of Use
Visual-Read HIV Test shall mean a rapid, non-digital diagnostic test for antibodies to HIV designed primarily to be read by the naked eye and to be used in a Point of Care environment. A Visual-Read HIV Test expressly excludes digital tests that include a reading device or integrated digital technology to aid in the interpretation or indication of the result.

IPSCIO Record ID: 300607

License Grant
The Company has the rights to use certain raw materials in the manufacture of Vitamin D diagnostic tests.
License Property
Vitamin D diagnostic tests are for reagents that are used in its FastPack Vitamin D Assay.

The FastPack System is for the treatment of cancer and infectious diseases using nanoparticle coating technology similar to the core nanoparticle coating technology.

The FastPack System is a proprietary diagnostics platform launched in 2001. This novel, rapid and highly accurate immunoassay testing system consists of the FastPack Analyzer and the FastPack test pouch; a single-use, disposable, foil packet which includes the FastPack reagent chemistry. Since the initial conception of the system, the Company has developed two versions of its analyzer and test pouch (1.0 and IP) and has expanded its assay menu to 10, including tests for prostate cancer, thyroid function, metabolic disorders and research applications.

Field of Use
FastPack® IP Vitamin D Immunoassay
Vitamin D, known as the sunshine vitamin, is part of a group of fat-soluble prohormones which encourage the metabolism of calcium and phosphorus in the body. Increasing research is now uncovering evidence illustrating the importance of vitamin D in the protection against a whole host of health issues. It is also estimated that as much as half the population in the world is deficient in vitamin D. The FastPack® IP Vitamin D immunoassay is intended for the quantitative determination of total 25-hydroxyvitamin D and other hydroxylated metabolites in human serum and plasma. This assay is designed for use with the FastPack® IP System which is designed specifically for use in the practice laboratory setting.

IPSCIO Record ID: 4047

License Grant
The Company announced a development Agreement with the Licensee, for the development of a new multiplex product that would be developed on DPP®, Dual Path Platform, and which would be marketed exclusively by the Licensee under an exclusive limited DPP® License.

The Agreement with the Licensee contemplated that the Company would enter into a License Agreement subject to the satisfaction of certain development and other conditions.  

On January 19, 2009, the Licensor granted, effective December 31, 2008, a limited exclusive License within a defined field of application for the Licensor's DPP® technology to the Licensee.

License Property
The Company’s main products are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA in 2006; the third is sold for export only. All of the Company’s products that are currently being developed are based on its patented Dual Path Platform (DPP®), which is a unique diagnostic point-of-care platform that has certain advantages over lateral flow technology. The Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007.

IPSCIO Record ID: 211873

License Grant
For TMA Qual Assays for Existing Instruments, Licensor grants a worldwide, non-exclusive, non-transferable, right and license, with no right to grant any sublicense to any Third Party, to research, develop, make, have made, use, import, offer to sell and sell Licensed Products for Existing Instrumentation.

For TMA Qual Assays for Future Instruments, Licensor grants a worldwide, non-exclusive, non-transferable right and license, with no right to grant any sublicense to any Third Party,

For the Option to Extend License{s), Licensor grants an option to extend the period(s) of these license rights granted.

License Property
The property include instrumentation, assays and patents.

bDNA means the fundamental branched nucleic acid method of signal amplification of nucleic acids.

bDNA Nucleic Acid Assays means Nucleic Acid Assays with respect to which bDNA is the sole method of amplification.

Blood Screening means (i) the screening of blood, plasma or blood components intended for transfusion or for use in blood products (e.g., immunoglobulins), and (ii) the screening of any biological materials intended for transfusion or transplantation, in each case, from any donor, including autologous donors.

HCV means hepatitis C virus.
HIV means human immunodeficiency virus.

Field of Use
Licensed is for nucleic acid test (NAT) for the detection of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) in donated blood.

IPSCIO Record ID: 287575

License Grant
An undisclosed third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes.
License Property
The products and processes for diagnostic, industrial and research and development purposes target the detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”) and target sepsis and Lyme disease.
Field of Use
The Company is using its T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”).

IPSCIO Record ID: 626

License Grant
Licensor  is willing to grant to Licensee a royalty-bearing, worldwide non-exclusive  license under the Licensed Patents.
License Property
Licensed Products shall mean Urine-based  immunoassays and serum, plasma, oral fluid or whole Blood-based  Immunoassays (i) which have a composition containing an HIV-2 antigen,  (ii) which are manufactured, used or sold by Licensee or its Affiliate and are capable of detecting HIV 1/2 antibodies and/or  antigen only on Licensee's Point of Care Rapid Test platform.

Licensed Patents
HIV-2 (Foundational)
EP 0239 425; EP 0 320 495; EP 284 383; EP 283 327
US 4,839,288; US 5,030,718; US 5,055,391; US 5,066,782;
US 5,268,265; US 5,364,933; US 5,051,496; US 5,770,703; US 5,830,641; US 5,079,342; US 6,048,685; US 6,162,439; US 6,261,762; US 6,265,149; US 6,322,964; US 5,306,614;
US 5,580,739; US 6,518,015

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.